The Role of Microglia in AD Pathogenesis and Treatment
About the Research Project
Program
Award Type
Standard
Award Amount
$99,892
Active Dates
April 01, 2004 - March 31, 2006
Grant ID
A2004274
Mentor(s)
Cynthia Lemere, PhD, Harvard Medical School, Brigham and Women's Hospital
Summary
One of the hallmarks of Alzheimer’s disease (AD) is the accumulation of a protein called beta-amyloid (Aß) in the brain. This protein is formed throughout life, but as some individuals age, the protein begins to accumulate in aggregates called plaques. Surrounding the Aß plaques in the brain is an area of inflammation that involves the immune cells of the brain, called the microglia. Microglia produce both noxious substances that can increase the damage to the brain caused by Aß and helpful substances that help brain cells maintain normal function. Dr. Seabrook is studying the effects of suppressing microglia on the formation of plaques in mice that have been engineered to produce an abnormal human form of Aß in their brain. These experiments will help elucidate the basic role of microglia in the formation of Aß. The role of microglia during vaccination will also be examined, which could lead to a better understanding of their role in this promising therapeutic area.
Related Grants
Alzheimer's Disease Research
Defining Immunometabolic Contributions to Cognitive Impairment in Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Caleb Bailey, PhD
Current Organization
University of Kentucky Research Foundation
Defining Immunometabolic Contributions to Cognitive Impairment in Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Caleb Bailey, PhD
Current Organization
University of Kentucky Research Foundation
Alzheimer's Disease Research
Understanding the Link Between Alzheimer's Disease Risk Genes and Immune Responses in the Brain
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Amanda McQuade, PhD
Current Organization
University of California, San Francisco
Understanding the Link Between Alzheimer's Disease Risk Genes and Immune Responses in the Brain
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Amanda McQuade, PhD
Current Organization
University of California, San Francisco
Alzheimer's Disease Research
Developing a Noninvasive Gene Therapy for Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Dominika Pilat, PhD
Current Organization
Massachusetts General Hospital
Developing a Noninvasive Gene Therapy for Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Dominika Pilat, PhD
Current Organization
Massachusetts General Hospital